NCT06113900View on ClinicalTrials.gov

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

January 30, 2025

Conditions
Lupus Nephritis
Interventions
DRUG

Dapagliflozin 10mg Tab orally once daily

Sodium glucose co-transporter 2 inhibitors

Trial Locations (1)

Unknown

Ain Shams University, Alexandria

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06113900 - Assessment of Safety and Efficacy of SGLT2is Among LN Patients | Biotech Hunter | Biotech Hunter